Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk invited to work there." This was something that Salk was deprived of early in his life, but due to his achievements, was able to provide for future scientists. In 1966, Salk described his "ambitious plan for the creation of a kind of Socratic academy where the supposedly alienated two cultures of science and humanism will have a favorable atmosphere for cross-fertilization." Author and journalist Howard Taubman explained: "The New York Times", in a 1980 article celebrating the 25th anniversary of the Salk vaccine, described the current workings at the facility: At the institute, a magnificent complex of laboratories and study